Drug Trial Radar · NCT04904471
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39,663
Actual
Start
Jun 15, 2021
Primary completion
Jan 31, 2022
Study completion Nov 1, 2023
Sponsor
- Lead sponsor
- WestVac Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- West China Hospital
- First posted
- May 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who do not have a known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 or SARS-CoV-2 infection.
Conditions
- COVID-19
Interventions
Recombinant COVID-19 vaccine (Sf9 cells)Biological
This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
Placebo controlOther
Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Virologically confirmed (polymerase chain reaction(PCR) positive) symptomatic COVID-19 cases first occurring, regardless of severity.Time frame: 28 days after completion of 3 doses vaccination.
- The incidence of serious adverse events(SAEs).Time frame: Day 0 to 6 months after completion of 3 doses vaccination.
- The incidence of adverse event of special interests(AESIs).Time frame: Day 0 to 6 months after completion of 3 doses vaccination.
- The incidence of medically attended adverse events(MAAEs).Time frame: Day 0 to 6 months after completion of 3 doses vaccination.
- The incidence of solicited adverse events(AEs).Time frame: 0 to 7 days after each dose vaccination
- The incidence of unsolicited adverse events(AEs) .Time frame: 0 to 21 days after the first dose and the second dose vaccination, and 0 to 28 days after the third dose vaccination
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Permata Hospital
Bekasi, Indonesia
Brawijaya University Hospital
Malang, Indonesia
Universitas Muhammadiyah Malang Hospital
Malang, Indonesia
Airlangga University Hospital
Surabaya, Indonesia
Husada Utama Hospital
Surabaya, Indonesia
Puskesmas Ciketingudik
Bekasi, Jiangsu, Indonesia
Moi Teaching and Referral Hospital,Eldoret (MTRH)
Eldoret, Kenya
KAVI-Institute of Clinical Research, University of Nairobi
Nairobi, Kenya
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
Durango, Mexico
Centro de Investigación Clínica y medicina traslacional (CIMeT)
Guadalajara, Mexico
Hospital General Dr. Manuel Gea González
Mexico City, Mexico
Invesclinic MX
Mexico City, Mexico
Clínica de Enfermedades Crónicas y de Procedimientos Especiales
Morelia, Mexico
SMIQ,S de R.L. de C.V.
Querétaro, Mexico
FS Scientia Pharma SA de CV
San Luis Potosí City, Mexico
Bharatpur Hospital
Kathmandu, Nepal
Perpetual Succour Hospital - The Research Institute
Cebu City, Philippines
St Luke Medical Centre - BGC
City of Taguig, Philippines
De La Salle Medical and Health Sciences Institute
Dasmariñas, Philippines
The Medical City - Iloilo
Iloilo City, Philippines
West Visayas State University Medical Center
Iloilo City, Philippines
Tropical Disease Foundation
Makati City, Philippines
Makati Medical Center
Makati City, Philippines
Quirino Memorial Medical Center
Quezon City, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.